Efficacy and Safety of Combined Topical Lidocaine and Tetracaine Cream for Facial Fractional Laser Resurfacing Compared With Its Reference Product in Chinese Adults: A Multicenter, Randomized, Double-Blind Phase 3 Study.
Wenxin Yu, Zhongling Luo, Yi Zhao, Zhiqi Hu, Aijun Zhang, Yong Li, Juan Tao, Xiaosong Chen, Haiying Wang, Liying Chen, Hanjie Zhu, Xiaoxi Lin
J Cosmet Dermatol 24(8) e70358
摘要
摘要
BACKGROUND: As a potentially effective anesthetic, CU-30101 is comprised of 7% lidocaine and 7% tetracaine and is a generic drug of Pliaglis. This study aimed to investigate the equivalence between CU-30101 and Pliaglis as topical anesthetics for fractional laser. METHODS: This Phase 3 trial recruited Chinese adults scheduled for facial fractional laser resurfacing. Participants were randomized to receive opposite treatment sequences of CU-30101 and Pliaglis on contralateral sides of the face prior to laser application. Visual Analog Scale (VAS), participant and investigator satisfaction ratings, local tolerability, and safety were assessed. RESULTS: Two hundred eighty-four participants completed the study, with mean VAS scores of 35.3 ± 24.51 for CU-30101 and 37.3 ± 24.17 for Pliaglis. The 95% confidence interval of -3.78 to -0.13 for the VAS difference laid within the predefined equivalence margin of ±4.7, confirming equivalence in efficacy. The results in the per-protocol set further corroborated the equivalence. Both participants and investigators expressed consistently high satisfaction with CU-30101 and Pliaglis. Furthermore, both treatments were well tolerated and exhibited favorable safety profiles. CONCLUSION: This study demonstrated the equivalent efficacy of CU-30101 to its reference product, Pliaglis, among Chinese adults undergoing facial fractional laser resurfacing. CU-30101 showed commendable local tolerability and safety profiles, consistent with those of Pliaglis.
KM 提取结果
0 个 Figure · 0 个 KM 面板
其他 Figure(1,默认折叠)
这些图片未产生 KM 曲线结果,不在主页面重复展示。